Clinical trials: Androgens
Prostate Cancer, Osteoporosis
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen
- Trial name
- NCT01025479
- Where
- 18 sites in South Korea
- Volunteers
- 829 people
- Sponsor
- AstraZeneca
Prostate Cancer
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival.
- Trial name
- FAST-NL (NCT01215526)
- Where
- 47 sites in Netherlands
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Acne Vulgaris
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in study participants with acne vulgaris that participated in the Phase 3 pivotal…
- Trial name
- NCT02682264
- Testing
- CB-03-01 cream, 1%
- Where
- 74 sites in United States, Bulgaria and 5 more
- Volunteers
- 609 people
- Sponsor
- Cassiopea SpA
Acne Vulgaris
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9…
- Trial name
- NCT02720627
- Testing
- cortexolone 17α-propionate
- Where
- 10 sites in United States, Poland
- Volunteers
- 27 people
- Sponsor
- Cassiopea SpA
Acne Vulgaris
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in subjects with acne…
- Trial name
- NCT01831960
- Testing
- cortexolone 17α-propionate
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Intrepid Therapeutics, Inc.
Prostatic Neoplasms
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.
- Trial name
- NCT00121095
- Testing
- Samarium Sm-153 lexidronam + Docetaxel
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Cytogen Corporation
Androgenetic Alopecia
Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Previous studies of finasteride treatment in women with hair loss have failed to show positive results, yet, some women have responded anecdotally.
- Trial name
- NCT01052870
- Testing
- Finasteride
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- HairDx, LLC
Prostate Cancer
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
This is the first study of MLN2704 administered to humans. The purpose of the study is to determine the highest dose of MLN2704 that can be given safely to patients with prostate cancer, and to identify any side effects…
- Trial name
- NCT00052000
- Testing
- MLN2704 (DM1 conjugated monoclonal antibody MLN591)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Locally Advanced Prostate Cancer
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
While radiation therapy with androgen ablation (hormone reduction) is the standard method of treating locally advanced prostate cancer.
- Trial name
- NCT01048151
- Testing
- TNFerade™ Biologic
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GenVec
Acne Vulgaris
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent skin disorder. The purpose of this study is to compare the safety and efficacy of multiple concentrations of CB-03-01 to vehicle in the…
- Trial name
- NCT01631474
- Testing
- CB-03-01, Vehicle
- Where
- 13 sites in United States
- Volunteers
- 363 people
- Sponsor
- Intrepid Therapeutics, Inc.
Prostate Cancer
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients
The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer.
- Trial name
- NCT00895466
- Testing
- PEP-223/CoVaccine HT
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Pepscan Therapeutics
Prostatic Neoplasms
Taxotere Prostate Cancer New Indication Registration Trial in China
To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and prednisone in subjects with hormone-refractory metastatic prostate cancer.
- Trial name
- NCT00436839
- Testing
- Docetaxel, Mitoxantrone, Prednisone
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Sanofi
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT02608476
- Testing
- CB-03-01 cream, 1%, Vehicle cream
- Where
- 52 sites in United States, Bulgaria and 4 more
- Volunteers
- 732 people
- Sponsor
- Cassiopea SpA
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT02608450
- Testing
- CB-03-01 cream, 1%, Vehicle cream
- Where
- 54 sites in United States, Georgia and 1 more
- Volunteers
- 708 people
- Sponsor
- Cassiopea SpA
Acne
Topical ASC-J9 Cream for Acne
To evaluate the safety and efficacy of topical 0.1% and 0.025% ASC-J9 creams applied twice daily for facial acne compared to vehicle control.
- Trial name
- NCT01289574
- Testing
- ASC-J9
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 181 people
- Sponsor
- AndroScience Corp
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca